All In Biotech

Drug Trial Radar · NCT07138001

Phase 2 Clinical Trial of KH617

A Randomized, Controlled, Open-label, Multicenter Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of KH617 in Combination With Temozolomide Versus Investigator's Choice Treatment or KH617 Monotherapy for Recurrent Glioblastoma

Last checked: Nov 19, 2026Latest source record: Aug 22, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

60

Planned (sponsor's estimate)

Start

Aug 2025

Primary completion

Sep 2027

Study completion Dec 2030

Sponsor

Sponsor type
Industry
First posted
Aug 22, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To evaluate the efficacy and safety of KH617 for injection in combination with temozolomide versus investigator's choice therapy or KH617 monotherapy for recurrent glioblastoma

Conditions

  • Recurrent Glioblastoma

Interventions

  • KH617+TMZCombination product

    use KH617 and TMZ(5/28) as Combination Product.

  • KH617Drug

    Single Clinical trial investigational drug

  • TPC: TMZ or Platinum (cisplatin or carboplatin)+VP-16Drug

    Comparator product, Two treatment options for physicians and subjects to choose from: 1. use TMZ(7/7) 2. Use Platinum (cisplatin or carboplatin)+VP-16

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. ORRTime frame: 54 weeks
  2. PFS-6Time frame: 54 weeks
  3. TEAETime frame: 54 weeks

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.